CFG

PAH
Total support: $150,000

Intended Format: Grand Rounds – Live/Enduring, Minute-CME/CME Blast, other

Intended Audience: Fellows, Early career physicians

Bayer TA Rationale for Educational Support:

Highest priority will be given to programs whose main focus is:

• Understanding the role of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway on the pathophysiology and progression of PAH, highlighting differences in MOA between approved drugs acting on this pathway.
• Understanding how to utilize combination and transition treatment strategies to optimize and individualize PAH therapy
• Management of PAH with emphasis on most recent ESC/ERS guidelines risk stratification strategies and importance of goal directed therapy highlighting REPLACE data.

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning Objectives
• Proposed Faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan
• Detailed budget

Provider Justification:

Copy of most recent accreditation letter and status

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

• Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(6):573-584. doi:10.1016/S2213-2600(20)30532-4
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension [published correction appears in Eur Heart J. 2023 Apr 17;44(15):1312]. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237)